Establishing a Treatment Method for Behçet's Disease Uveitis Utilizing the Measurement of Infliximab Blood Concentration

2023 Fiscal Year Final Research Report

• Project/Area Number: 19K18851
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56060:Ophthalmology-related
• Research Institution: Jichi Medical University
• Principal Investigator: Watanabe Meri 自治医科大学, 医学部, 講師 (10646342)
• Project Period (FY): 2019-04-01 – 2024-03-31
• Keywords: ベーチェット病 / インフリキシマブ

Outline of Final Research Achievements

By measuring infliximab blood concentration and neutralizing antibodies against infliximab, we aim to customize the dosing intervals (treatment intervals). This approach not only prevents recurrence but also reduces the burden of　administration and hospital visits for patients who can extend the dosing interval beyond eight weeks. Additionally, although the current clinical practice guidelines for Bechet's disease include recommendations on dosing intervals, this approach may allow for a reevaluation of those guidelines.

Free Research Field

ぶどう膜炎

Academic Significance and Societal Importance of the Research Achievements

インフリキシマブの血中濃度およびインフリキシマブの中和抗体測定を行うことにより、投与間隔（治療間隔）のオーダーメイド化を図る。それによって再燃を防ぐこと、8週間以上投与間隔をあけられる患者の、投与及び通院の負担を軽減させることに、社会的な意義がある。